Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05056207 · ClinicalTrials.gov registry record · NA
PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema
A NA study of Lymphedema, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 260
- Enrollment target
- 1
- Study location
NCT05056207: Active NA study of Lymphedema, sponsored by M.D. Anderson Cancer Center.
NCT05056207 is a NA study of Lymphedema that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 260 participants, below the 9,292-participant average among 34 other Lymphedema trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05056207, a NA study of Lymphedema, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 260 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is to learn about breast cancer patients' opinions about screening for lymphedema (a side effect of breast cancer treatment in which the arm can become heavy, painful, and/or swollen) and their satisfaction with the lymphedema screening program.
Conditions Studied
Interventions
- OTHER Cohort I (patients receiving annual lymphedema screening
- OTHER Cohort II (patients followed intensively for lymphedema)
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2017-11-17 |
| Est. Completion | 2026-11-17 |
| Phase | NA |
What the registry record for NCT05056207 still lists
NCT05056207 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 9,292-participant average among 34 other Lymphedema trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Lymphedema appearing as the primary indexed condition, and to 2 interventions - of which Cohort I (patients receiving annual lymphedema screening is the first listed.
NCT05056207 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05056207 about?
NCT05056207 is a clinical study titled "PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema". This research study is to learn about breast cancer patients' opinions about screening for lymphedema (a side effect of breast cancer treatment in which the arm can become heavy, painful, and/or swollen) and their satisfaction with the lymphedema screening program.
What is the current status of trial NCT05056207?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 260 participants. The study started on 2017-11-17. Estimated completion is 2026-11-17.
What conditions does trial NCT05056207 study?
This clinical trial studies the following conditions: Lymphedema.
What interventions are being tested in trial NCT05056207?
The interventions under investigation include: Cohort I (patients receiving annual lymphedema screening (OTHER), Cohort II (patients followed intensively for lymphedema) (OTHER).
Who is sponsoring clinical trial NCT05056207?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05056207 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05056207's enrollment target sits among peer trials
260 10th of 34 higher than 25 of 34 other Lymphedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)
RECRUITING · NA
-
Clinical Study to Evaluate the Effectiveness and Health Economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for Lymphedema/Phlebolymphedema
RECRUITING · NA
-
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
RECRUITING · NA
-
Pedal Pump and Leg Lymphedema
RECRUITING · NA
-
Comparing Two Ways to Manage Head and Neck Lymphedema
RECRUITING · NA
-
LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI